Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Auxilium Pharmaceuticals

Request full access

Develops and markets pharmaceutical products that focus on urology and sexual health

Tredyffrin Township, United StatesFounded 1999Biotech & Life Sciences

About Auxilium Pharmaceuticals

Auxilium Pharmaceuticals, Inc. was a specialty biopharmaceutical company founded in 1999 with a strategic focus on developing and marketing products for urology and men's health. The company established a significant market presence through a portfolio of 12 approved products, addressing conditions such as erectile dysfunction, testosterone replacement, and Peyronie's disease.

Key products in its commercial portfolio included XIAFLEX, a biologic treatment for Dupuytren's contracture and Peyronie's disease; Testim, a testosterone gel for hypogonadism; and TESTOPEL, an implantable testosterone replacement therapy. The company's business model revolved around the development and commercialization of these specialist-focused pharmaceutical products. A significant milestone was the 2013 acquisition of Actient Holdings LLC for $585 million, a move that created a more comprehensive urology platform and expanded its testosterone replacement therapy offerings.

In a culminating event for the company, Auxilium was acquired by Endo International plc in a transaction valued at approximately $2.6 billion, announced in October 2014 and completed in January 2015. This acquisition was positioned as a strategic move to enhance Endo's branded pharmaceuticals business by integrating Auxilium's complementary portfolio, particularly strengthening its offerings in urology and orthopedics. The deal followed Auxilium's rejection of an earlier, lower offer from Endo and the termination of a planned merger with QLT Inc. Following the acquisition, Auxilium's common stock ceased trading on the NASDAQ Global Market.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
128
Open positions
None listed
Dealroom signal
67.4/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Trading, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Sep 2014 $2.6B $2.6B Endo Pharmaceuticals Inc —
IPO✓Exit Jul 2004 $41M $160M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Auxilium Pharmaceuticals website traffic

Latest recorded traffic for Auxilium Pharmaceuticals is 980 monthly website visits, down 10.9% over the last three months. Auxilium Pharmaceuticals's team declined 8.6% over the past year.

Latest monthly visits980 3-month web change-10.9% 1-year team growth-8.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Auxilium Pharmaceuticals in the Tredyffrin Township ecosystem

Live from Dealroom

The Auxilium Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • SV Health Investors

Series B and later8 investors entered at this stage

  • Lehman Brothers
  • Schroders
  • OrbiMed
  • Perseus-Soros Biopharmaceutical Fund
  • CIP Capital
  • Sprout Group
  • SCP Partners
  • BB Biotech Ventures

Other known investors3 additional known investors

  • Endo Pharmaceuticals Inc
  • Aisling Capital
  • New Leaf Venture Partners
Team profiled 20 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States97.1%
🇬🇧 United Kingdom2.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Auxilium Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Auxilium Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.